TSHA Q1 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-27.5% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$24M-713.3% margin

Net Income

-$24M-705.4% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-5.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$153M

Total Liabilities

$99M

Stockholders' Equity

$54M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$5M	-27.5%
Gross Profit	$3M	$4M	-16.3%
Operating Income	-$24M	-$17M	-46.9%
Net Income	-$24M	-$18M	-36.5%